Lung Cancer Clinical Trial
Official title:
A Pilot Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer
The goal of this clinical research study is to compare armodafinil and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.
The Study Drugs:
Armodafinil is designed to prevent excessive sleepiness.
Minocycline is an antibiotic. Minocycline has been shown to interrupt cytokine production,
which may help to reduce multiple symptoms.
A placebo is not a drug. It looks like the study drug but is not designed to treat any
disease or illness. It is designed to be compared with a study drug to learn if the study
drug has any real effect.
Study Groups:
If you agree to take part in this study, you will be randomly assigned (as in the roll of
dice) to join 1 of 4 groups.
- Group 1 will take armodafinil and a placebo.
- Group 2 will take minocycline and a placebo.
- Group 3 will take armodafinil and minocycline.
- Group 4 will take placebos alone.
Neither you nor the study staff you will see in the clinic will know if you are receiving the
study drug(s) and/or the placebo(s). However, if needed for your safety, the study staff will
be able to find out which study drug you are receiving.
If needed, during this study, you may receive standard care by your treating doctors.
Study Drug Administration:
You will take the study drug(s)/placebos every day for 10 weeks. You should take the
drug(s)/placebo(s) with a full glass of water. If you get an upset stomach, take them with
food.
You will be given pamphlets with more information about how to take the study drugs/placebos.
You should bring your study drug/placebo capsules to the clinic every study visit.
Completing the Symptom Questionnaire:
Throughout the study, you will be asked to complete the symptom questionnaire. You will be
asked about symptoms from therapy you may be experiencing and how they may be interfering
with your daily activities. The study staff will either meet you during your regular clinic
visit or call you at your home at a time that is convenient for you. In the clinic, you will
complete the questionnaire by paper and pen, or by entering your answers into an electronic
tablet computer. On the phone, study staff will ask you the questions and record your answers
on paper or enter them into a computer. You will complete the symptom questionnaire before
you begin chemoradiation and then 1 time a week during Weeks 1-16 of the study. The symptom
questionnaire will take up to 5 minutes to complete.
Study Visits:
Before you begin chemoradiation:
- You will complete 4 questionnaires about pain and other symptoms, your mood, and your
quality of life. Completing all 4 of the questionnaires will take about 15 minutes.
- If you are able to become pregnant, you will have a urine pregnancy test. The study
staff will give you the pregnancy test kit at your scheduled visit, and will review and
record the results of the test before you can pick up the study drugs from the pharmacy.
The pregnancy test will be repeated at weeks 1, 4, 7, and 12 (or at the first follow-up
clinic visit post-treatment) and 30 days after the study drugs are stopped .
During the last week of chemoradiation (about Week 7):
-You will complete 3 questionnaires about your symptoms, mood, and quality of life. These
questionnaires will take about 10 minutes total to complete.
After about Week 7, the study staff will call you 1 time a week to check on you until Week
10. This phone call should last only a few minutes. If you have had several side effects from
chemoradiation, this phone call may take longer.
About Week 12 (or at the first routine follow-up clinic visit post-treatment):
- You will complete the 3 questionnaires about your symptoms, mood, and quality of life.
- If you were smoking at the beginning of the study, you will complete a questionnaire
that asks if you stopped smoking any time during the study. This will take a few minutes
to complete.
- You will be asked to complete another questionnaire that asks about your satisfaction
with the study drug(s). This will take a few minutes.
Length of Study:
You will be on study for about 16 weeks. You will take the study drug(s) for 10 weeks and
complete the symptom survey until Week 16. You will be taken off study early if you have
intolerable side effects.
This is an investigational study. Armodafinil is FDA approved and commercially available for
the treatment of excessive sleepiness. Minocycline is FDA approved and commercially available
for the treatment of bacterial infections. The use of these drugs to help reduce
chemoradiation symptoms is investigational.
Up to 12 patients will take part in this study. All will be enrolled at MD Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|